48/100
Opportunity
Commercial fit6/25
Clinical timing20/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5
New phase 1 trial NCT07535112 posted by Bayer: "A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation". New trial on a phase 1 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).
Why nowClinicalTrials.gov record updated 64 days ago.
ConfidenceHigh · 87%